« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 123, Issue 2
, Pages 443-451
, February 2009
Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-γ–producing CD8+ T cells
References
- . The burden of atopy and asthma in children. Allergy. 2004;59(suppl 78):7–11
- . The public health implications of asthma. Bull World Health Organ. 2005;83:548–554
- . The allergy epidemic extends beyond the past few decades. Clin Exp Allergy. 2004;34:1007–1010
- . Food anaphylaxis. Clin Exp Allergy. 2007;37:651–660
- . Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191–193
- . Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380–384
- . Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol. 2003;112:1203–1207
- . Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol. 2007;120:491–503
- . Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99:744–751
- . Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256–262
- Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986–993
- Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol. 2001;108:639–646
- The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol. 2005;115:171–178
- . Pharmacological and immunological effects of individual herbs in the Food Allergy Herbal Formula-2 (FAHF-2) on peanut allergy. Phytother Res. 2008;22:651–659
- . Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy. 2007;37:846–855
- . Pharmacopoeia of the People's Republic of China. 6th ed.. Beijing: People's Medical Publishing House; 2005;
- The US Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Guidance for industry botanical drug products. Revised ed. Rockville (MD):2004.
- . A murine model of IgE mediated cow milk hypersensitivity. J Allergy Clin Immunol. 1999;103:206–214
- Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol. 2001;108:639–646
- . Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin Exp Immunol. 1993;92:323–327
- . CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. Proc Natl Acad Sci U S A. 1992;89:11612–11616
- . Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice. Infect Immun. 2006;74:4339–4348
- The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut-allergic children. Clin Exp Allergy. 2000;30:1135–1143
- Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162:5624–5630
- . IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest. 2006;116:833–841
- . Human TH1 and TH2 subsets: doubt no more. Immunol Today. 1991;12:256–257
- . The role of lymphocytes in allergic disease. J Allergy Clin Immunol. 2000;105:399–408
- . Severely impaired IL-12/IL-18/IFNgamma axis in patients with hyper IgE syndrome. Eur J Clin Invest. 2005;35:718–721
- IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene. J Immunol. 2006;177:5006–5013
- . Endogenous IFN-gamma and IL-18 production directly limit induction of type 2 immunity in vivo. Eur J Immunol. 2002;32:3536–3545
- . Bacterial regulation of intestinal immune responses. Inflamm Bowel Dis. 2000;6:116–122
- . An analysis of interferon gamma, IL-4, IL-5 and IL-10 production by ELISPOT and quantitative reverse transcriptase-PCR in human Peyer's patches. Cytokine. 1998;10:627–634
- Human Peyer's patch T cells are sensitized to dietary antigen and display a Th cell type 1 cytokine profile. J Immunol. 2000;165:5315–5321
- IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205–1214
- . CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation 30. J Immunol. 2002;168:216–223
- . An essential role for IL-18 in CD8 T cell-mediated suppression of IgE responses. J Immunol. 2007;178:4771–4778
- . Regulation of allergic airway inflammation by class I-restricted allergen presentation and CD8 T-cell infiltration. J Allergy Clin Immunol. 2007;119:226–234
- . Inhibition of human mast cell growth and differentiation by interferon gamma-1b. Exp Hematol. 1998;26:245–251
Supported by the Food Allergy Initiative and by National Institutes of Health grant #AT001495-01A1 awarded to X.-M.L.
Disclosure of potential conflict of interest: X.-M. Li has received research support from the National Institutes of Health/National Center for Complementary and Alternative Medicine and the Food Allergy Initiative; has provided legal consultation or expert witness testimony on the topic of food allergy; and shares a patent for Food Allergy Herbal Formula-2 with Herbal Springs, LLC. H. A. Sampson received research support from the National Institutes of Health/National Center for Complementary and Alternative Medicine and the Food Allergy Initiative; is a consultant/scientific advisor for the Food Allergy Initiative and president of the American Academy of Allergy, Asthma and Immunology; and is part-owner of Herbal Springs, LLC. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)03467-2
doi: 10.1016/j.jaci.2008.12.1107
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 123, Issue 2
, Pages 443-451
, February 2009
